SHP2 inhibition diminishes KRAS(G12C) cycling and promotes tumor microenvironment remodeling

KRAS is the most frequently mutated human oncogene, and KRAS inhibition has been a longtime goal. Recently, inhibitors were developed that bind KRAS(G12C)-GDP and react with Cys-12 (G12C-Is). Using new affinity reagents to monitor KRAS(G12C) activation and inhibitor engagement, we found that an SHP2...

Descripción completa

Detalles Bibliográficos
Autores principales: Fedele, Carmine, Li, Shuai, Teng, Kai Wen, Foster, Connor J.R., Peng, David, Ran, Hao, Mita, Paolo, Geer, Mitchell J., Hattori, Takamitsu, Koide, Akiko, Wang, Yubao, Tang, Kwan Ho, Leinwand, Joshua, Wang, Wei, Diskin, Brian, Deng, Jiehui, Chen, Ting, Dolgalev, Igor, Ozerdem, Ugur, Miller, George, Koide, Shohei, Wong, Kwok-Kin, Neel, Benjamin G.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Rockefeller University Press 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7549316/
https://www.ncbi.nlm.nih.gov/pubmed/33045063
http://dx.doi.org/10.1084/jem.20201414

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7549316/
https://www.ncbi.nlm.nih.gov/pubmed/33045063
http://dx.doi.org/10.1084/jem.20201414

Ejemplares similares